This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: BMY to Buy Forbius, BMRN Gets CRL & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with drug approvals, and regulatory and other pipeline updates.
BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism
by Zacks Equity Research
BioMarin's (BMRN) BLA for vosoritide is based on final data from a phase III study, long-term data from the ongoing phase II and phase III extension studies and extensive natural history data.
BioMarin Down on CRL From FDA for Hemophilia A Candidate
by Zacks Equity Research
BioMarin (BMRN) suffers a setback as the FDA issues a CRL to its BLA for the gene therapy Roctavian, developed to treat patients with severe hemophilia A. Shares fall as a result.
BioMarin's MAA for Dwarfism Candidate Gets EMA Validation
by Zacks Equity Research
The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.
Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU
by Zacks Equity Research
Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BMRN) Outperforming Other Medical Stocks This Year?
BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact
by Zacks Equity Research
BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 100.00% and 2.74%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.
AbbVie's (ABBV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AbbVie (ABBV) beats on second-quarter 2020 earnings and revenues. Shares up in pre-market trading.
Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up
by Zacks Equity Research
Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.
Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.
Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat
by Zacks Equity Research
Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.
BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
BioMarin (BMRN) is likely to provide an update on the sales of its key drugs Vimizim, Kuvan and others as well as how the pipeline has progressed when it reports Q2 earnings.
Alexion (ALXN) Beats on Q2 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Alexion (ALXN) beats on earnings and sales in the second quarter of 2020.
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues decline year over year in first-quarter fiscal 2021.
Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker
by Zacks Equity Research
Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.
Mustang Bio (MBIO) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Mustang Bio (MBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
PhaseBio Initiates Phase II Study for Coronavirus Patients
by Zacks Equity Research
PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.
Dynavax Signs a Pact to Develop Universal Influenza Vaccine
by Zacks Equity Research
Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. The development is funded under a contract win from NIAID.
Tricida (TCDA) Plummets on Regulatory Update on Veverimer
by Zacks Equity Research
Tricida (TCDA) tanks on FDA notification about the identification of deficiencies in its ongoing review of the NDA for pipeline candidate, veverimer (TRC101).
Nabriva Soars on Agreement With Merck to Distribute Sivextro
by Zacks Equity Research
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
Trevena (TRVN) Looks Good: Stock Adds 8.8% in Session
by Zacks Equity Research
Trevena (TRVN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.